ASCO data bring new markets within reach for two AstraZeneca therapies

AstraZeneca stole the show at ASCO on Friday with data that should help propel its top-grossing cancer drug and one of its newest market entrants into broadly expanded patient populations, as long as physicians adopt genetic testing in the new indications.

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported at the American Society of Clinical Oncology meeting that Tagrisso osimertinib increased disease-free survival in an adjuvant setting for early-stage, EGFR-mutant non-small cell lung cancer (NSCLC), setting it on a path to become the first targeted therapy in the adjuvant setting for the indication...